本文選題：復(fù)方青花顆粒 + 病毒性上呼吸道感染��； 參考：《福建中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的：觀察復(fù)方青花顆粒治療病毒性上呼吸道感染風(fēng)熱犯肺證的臨床療效及安全性。方法：1、病例來源及分組：本課題病例全部來源于2015年1月至2015年12月南京軍區(qū)福州總醫(yī)院就診的患者,共收治60例,年齡18-32歲。采用中央隨機(jī)系統(tǒng)軟件產(chǎn)生隨機(jī)號(hào)碼,按患者住院順序隨機(jī)分配至試驗(yàn)組與對(duì)照組。其中,試驗(yàn)組30例,對(duì)照組30例。2、治療方案：試驗(yàn)組予復(fù)方青花顆�？诜�,對(duì)照組予連花清瘟膠囊口服。兩組均予對(duì)癥支持處理,治療不超過10 d。3、觀察指標(biāo)：治療開始前將兩組患者的年齡、性別、體重、就診時(shí)間、甲型流感病毒感染人數(shù)等個(gè)人資料進(jìn)行登記。并記錄治療前、治療24h后體溫,以及治療前與治療3d后各證候(發(fā)熱、咳嗽、頭痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹瀉)程度的人數(shù)、炎癥指標(biāo)(白細(xì)胞、中性粒細(xì)胞、淋巴細(xì)胞、C-反應(yīng)蛋白)的值和人數(shù)。同時(shí),觀察兩組間體溫恢復(fù)情況、總療效及病程等。4、安全性評(píng)價(jià)：記錄患者用藥過程中是否出現(xiàn)藥物不良反應(yīng)、中醫(yī)證型改變,記錄用藥前后血常規(guī)、腎功能、肝功能。5、統(tǒng)計(jì)學(xué)處理：數(shù)據(jù)資料輸入SPSS13.0軟件并使用SPSS13.0軟件統(tǒng)計(jì)分析,假設(shè)檢驗(yàn)取雙側(cè)檢驗(yàn)。P0.05為差異有統(tǒng)計(jì)學(xué)意義。P0.05,為差異無統(tǒng)計(jì)學(xué)意義。結(jié)果：1、治療前兩組間性別、年齡、就診時(shí)間等均無顯著性差異(P0.05),具有可比性。2、兩組間退熱、治療病程均無顯著差異(P0.05)。3、兩組間證候(發(fā)熱、咳嗽、頭痛、流涕、咽痛、肌肉酸痛、乏力、腹瀉)的療效無統(tǒng)計(jì)學(xué)差異(P0.05)。4、兩組均能有效退熱。5、治療3天后試驗(yàn)組中的3分組、2分組、1分組發(fā)熱治愈率分別是80.00%、84.21%、83.33%。對(duì)照組中的3分組、2分組、1分組發(fā)熱治愈率分別是100.00%、78.95%、50.00%。試驗(yàn)組發(fā)熱、咳嗽、頭痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹瀉治愈率分別為83.33%,56.67%、82.61%、61.11%、50.00%、75.00%、90.91%、91.30%、71.43%,對(duì)照組發(fā)熱、咳嗽、頭痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹瀉治愈率分別為76.67%、66.67%、85.71%、64.29%、50.00%、82.35%、100.00%、95.83%、100.00%。6、兩組間總療效無顯著性差異(P0.05)。試驗(yàn)組和對(duì)照組的治愈率分別是40.00%、46.67%�？傆行史謩e是83.33%、76.67%。7、全部入組患者用藥均未出現(xiàn)明顯檢驗(yàn)指標(biāo)異常及不良反應(yīng)。結(jié)論：復(fù)方青花顆粒與連花清瘟膠囊一樣,可以用于病毒性上呼吸道感染風(fēng)熱犯肺證治療,療效好,安全性高。1、復(fù)方青花顆粒與連花清瘟膠囊退熱、治療病程均無顯著差異。2、復(fù)方青花顆粒與連花清瘟膠囊總療效相當(dāng),發(fā)熱、咳嗽、頭痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹瀉等癥狀改善的療效相當(dāng)。3、復(fù)方青花顆粒與連花清瘟膠囊總體安全性均較高。4、從藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)上分析,復(fù)方青花顆粒優(yōu)于連花清瘟膠囊。
[Abstract]:Objective: to observe the clinical efficacy and safety of compound blue and white granule in treating viral upper respiratory tract infection. Methods: from January 2015 to December 2015, 60 patients aged 18-32 years were treated in Fuzhou General Hospital of Nanjing military region. The central random system software was used to generate random numbers, which were randomly assigned to the experimental group and the control group according to the order of hospitalization. Among them, 30 cases in the test group and 30 cases in the control group were treated with compound blue and white granules, and the control group with Lianhua Qingwen capsule. The two groups were treated with symptomatic support, and the treatment was not more than 10 d.3. the patients' age, sex, body weight, visiting time, number of influenza A virus infection and other personal data were registered before the beginning of treatment. The number of patients with different symptoms (fever, cough, headache, nasal obstruction, runny, sore throat, muscle ache, fatigue, diarrhea) before and after treatment were recorded. The value and number of neutrophils, lymphocytes and C-reactive proteins. At the same time, observe the recovery of body temperature, total curative effect and course of disease between the two groups, safety evaluation: record whether there are adverse drug reactions in the course of drug use, change of TCM syndrome type, record blood routine before and after medication, renal function, etc. Liver function. 5, statistical processing: data input SPSS13.0 software and use SPSS13.0 software statistical analysis, assuming that the bilateral test. P0.05 as the difference was statistically significant. P0.05, there was no statistical significance for the difference. Results there was no significant difference in sex, age and time of visit between the two groups before treatment (P 0.05), and there was no significant difference between the two groups (P 0.05). There was no significant difference in the course of treatment between the two groups (fever, cough, headache, runny, pharynx, muscle ache), and there was no significant difference in the course of treatment between the two groups (fever, cough, headache, runny, sore throat, muscle ache). There was no significant difference in the effect of fatigue and diarrhea between the two groups. Both groups could effectively relieve fever. After 3 days of treatment, the cure rate of fever in 3 groups and 2 groups was 84.21% and 83.33%, respectively. In the control group, the cure rate of fever in 3 groups and 2 groups was 100.00,78.95 and 50.005, respectively. The cure rates of fever, cough, headache, nasal obstruction, runny, sore throat, muscle ache, fatigue and diarrhea in the experimental group were 83.33 and 56.67 respectively. The cure rate of diarrhea was 76.67 and 66.67, respectively. There was no significant difference in the total curative effect between the two groups (P 0.05). The cure rate of test group and control group were 40.00and 46.67 respectively. The total effective rate was 83.33 and 76.67, respectively. Conclusion: compound blue and white granule and Lianhua Qingwen capsule can be used in the treatment of viral upper respiratory tract infection with wind heat and lung syndrome, the efficacy is good, the safety is high. The compound blue and white granule and Lianhua Qingwen capsule can relieve fever. There was no significant difference in the course of treatment. 2. The total curative effect of compound blue and white granules was similar to that of Lianhua Qingwen capsule, fever, cough, headache, nasal obstruction, runny, sore throat, muscle soreness, fatigue, etc. The effect of improving diarrhea and other symptoms was equal to .3.The overall safety of compound blue and white granule and Lianhua Qingwen capsule was higher than that of Lianhua Qingwen capsule. From the evaluation of pharmacoeconomics, compound blue and white granule was superior to Lianhua Qingwen capsule.
【學(xué)位授予單位】：福建中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 郭小燕;鐘成梁;胡思源;;小兒咳喘靈泡騰片治療小兒咳嗽風(fēng)熱犯肺證(急性上呼吸道感染)的臨床研究[J];中醫(yī)藥學(xué)刊;2006年06期

2 郭小燕;鐘成梁;胡思源;;小兒咳喘靈泡騰片治療小兒咳嗽風(fēng)熱犯肺證(急性支氣管炎)臨床研究[J];中國中醫(yī)藥信息雜志;2006年06期

3 莫柳芬;蔣文偉;;桑菊飲治療感染后咳嗽(風(fēng)熱犯肺證)的療效觀察[J];中醫(yī)藥導(dǎo)報(bào);2014年07期

4 ;[J];;年期

相關(guān)重要報(bào)紙文章 前2條

1 遼寧中醫(yī)藥大學(xué)附屬醫(yī)院 張明雪;風(fēng)熱犯肺證與熱邪壅肺證鑒別[N];中國中醫(yī)藥報(bào);2012年

2 郭志芳;抄方治病為什么不靈驗(yàn)[N];中國老年報(bào);2004年

相關(guān)碩士學(xué)位論文 前4條

1 駱雨;麻杏石甘湯合止嗽散加減治療急性支氣管炎（風(fēng)熱犯肺證）療效觀察[D];成都中醫(yī)藥大學(xué);2015年

2 陳華武;復(fù)方青花顆粒治療病毒性上呼吸道感染風(fēng)熱犯肺證的臨床觀察[D];福建中醫(yī)藥大學(xué);2016年

3 娜仁高娃;小兒宣肺糖漿治療風(fēng)熱犯肺證咳嗽的臨床研究[D];成都中醫(yī)藥大學(xué);2013年

4 李雪;暴貝止咳口服液治療咳嗽風(fēng)熱犯肺證的Ⅱ期臨床試驗(yàn)研究[D];吉林大學(xué);2014年

，

本文編號(hào)：1970727